Focused On-demand Library for Serine/threonine-protein kinase LMTK1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6ZMQ8

UPID:

LMTK1_HUMAN

Alternative names:

Apoptosis-associated tyrosine kinase; Brain apoptosis-associated tyrosine kinase; CDK5-binding protein; Lemur tyrosine kinase 1; p35-binding protein

Alternative UPACC:

Q6ZMQ8; O75136; Q6ZN31; Q86X28

Background:

Serine/threonine-protein kinase LMTK1, also known as Apoptosis-associated tyrosine kinase, plays a crucial role in neuronal differentiation. This protein, with alternative names such as Brain apoptosis-associated tyrosine kinase, CDK5-binding protein, and Lemur tyrosine kinase 1, is pivotal in the regulation of neuronal development.

Therapeutic significance:

Understanding the role of Serine/threonine-protein kinase LMTK1 could open doors to potential therapeutic strategies. Its involvement in neuronal differentiation positions it as a key target for developing treatments aimed at neurodegenerative diseases.